Today is the last day of summerThe last financials anticipated the multi-dose portion of the avenanthramide clinical study being initiated in the summer. We have yet to see the single-dose trial results or any preclinical results. They once believed using avenanthramide with a newer PGX carrier also was promising and another group recently published avenanthramide in yeast capsules with promising results.
While the 5X and 10X PGX scale-up was expected to be completed this month the last financials gave a timeline of this year potentially expanding the due date by a few months. PGX will be presented at a conference of engineers on October 8. PGX could quickly go from the current 10L pilot facility to being proven in a 100L facility which is the decision point for mass industrialization. The 5X scale-up to 50L brings the technology to small-scale commercial levels and PGX's first potential commercial revenue. PGX-YBG was recently published in the journal Biomaterials.
Wound healing results with the Angiogenesis Foundation were recently published in two articles and presented at a scientific conference. The results suggest CSIC could cut healing time by half and without scaring according to Dr. Li. We wait to hear about the next steps for this program. Gilles called earlier results a 'home run' and talked about a potential wound healing franchise.
Other programs are also undergoing evaluation as CSCI prepares for a fulsome update and to release its priorities moving forward.